Oxford Gene Technology releases latest version of CytoSure Interpret Software

OGT releases new CytoSure™ Interpret Software to enhance CNV detection

Oxford Gene Technology (OGT), The Molecular Genetics Company, is pleased to announce the latest version (4.5.3) of its class-leading CytoSure™ Interpret Software. Complimentary with all CytoSure array purchases, CytoSure Interpret Software is a powerful and easy-to-use package for the analysis of aCGH data, the gold-standard for copy number variation (CNV) detection. Offering an impressive combination of advanced features, including Automatic Aberration Classification, the software allows the choice of standardised or customised user-defined data analysis.

With this latest version, OGT have introduced several innovative new features that further facilitate and standardise the data analysis workflow in order to deliver rapid access to meaningful results. By using information available in online databases such as DECIPHER and settings defined by the user, the Automatic Aberration Classification enables users to configure the software to automatically perform an initial classification of any detected CNV, accelerating analysis and standardising the interpretation process.

CytoSure Interpret Software allows simultaneous access to sample and experiment information across a network, providing the potential for labs on multiple sites to access a central database. In situations where IT infrastructures don’t permit this, the software now provides the additional functionality for exporting sample and experiment information into other databases, further facilitating sharing of case information and aberration calls.

In addition to the free text phenotype field, users are also now able to use Standardised Phenotype (Human Phenotype Ontology - HPO) terms to simplify and normalise the phenotype description process via a HPO Phenotype Selector window.

Dr Ruth Burton, Product Manager for CytoSure said “CytoSure Interpret Software continues to be cited as a decisive factor when purchasing CytoSure arrays and was a major contributor to our recent success in a competitive NHS tender for the supply of oligo-based arrays for cytogenetics research. Our dedicated software development team are continually implementing enhanced features and capabilities in response to new product development and customer feedback, reflecting the overall OGT strategy to provide the most effective and high quality products, services and support.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Gene Technology. (2014, March 26). Oxford Gene Technology releases latest version of CytoSure Interpret Software. News-Medical. Retrieved on May 20, 2019 from https://www.news-medical.net/news/20140326/Oxford-Gene-Technology-releases-latest-version-of-CytoSure-Interpret-Software.aspx.

  • MLA

    Oxford Gene Technology. "Oxford Gene Technology releases latest version of CytoSure Interpret Software". News-Medical. 20 May 2019. <https://www.news-medical.net/news/20140326/Oxford-Gene-Technology-releases-latest-version-of-CytoSure-Interpret-Software.aspx>.

  • Chicago

    Oxford Gene Technology. "Oxford Gene Technology releases latest version of CytoSure Interpret Software". News-Medical. https://www.news-medical.net/news/20140326/Oxford-Gene-Technology-releases-latest-version-of-CytoSure-Interpret-Software.aspx. (accessed May 20, 2019).

  • Harvard

    Oxford Gene Technology. 2014. Oxford Gene Technology releases latest version of CytoSure Interpret Software. News-Medical, viewed 20 May 2019, https://www.news-medical.net/news/20140326/Oxford-Gene-Technology-releases-latest-version-of-CytoSure-Interpret-Software.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Oxford Gene Technology expands portfolio of fluorescence in situ hybridisation probes